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Summary
To better understand the origin of leukemic stem cells, we tested the hypothesis that all leukemia oncogenes could
transform committed myeloid progenitor cells lacking the capacity for self-renewal, as has recently been reported forMLL-
ENL. Flow-sorted populationsof commonmyeloid progenitors andgranulocyte-monocyteprogenitorswere transducedwith
the oncogenes MOZ-TIF2 and BCR-ABL, respectively. MOZ-TIF2-transduced progenitors could be serially replated in
methylcellulose cultures and continuously propagated in liquid culture, and resulted in an acute myeloid leukemia in vivo
that could be serially transplanted. In contrast, BCR-ABL transduction conferred none of these properties to hematopoietic
progenitors. These data demonstrate that some, but not all, leukemia oncogenes can confer properties of leukemic stem
cells to hematopoietic progenitors destined to undergo apoptotic cell death.
adult life, undergo an increased number of cell divisions, andIntroduction
therefore may have a greater opportunity than more short-lived
cells to acquire the minimum number of mutations required forLimitless self-renewal potential is one of the hallmarks of all
malignant transformation (Bradford et al., 1997; Chesier et al.,cancers (Hanahan and Weinberg, 2000). It had been thought
1999; Lansdorp, 1997). Phenotypic evidence also implicatesthat all cells of a tumor contained such potential. However,
somatic stem cells as the target cells for transformation. Bothrecent evidence from human malignancies, including acute my-
stem cells and tumor cells express similar levels of telomeraseeloid leukemia (AML) (Bonnet and Dick, 1997), acute lympho-
(Morrison et al., 1996) required to maintain telomere length andblastic leukemia (ALL) (Cobaleda et al., 2000), and breast (Al-
prevent replicative senescence. In human AML, the distinctiveHajj et al., 2003) and CNS (Hemmati et al., 2003; Ignatova et
leukemia “stem cell” that is sufficient to generate AML in theal., 2002; Singh et al., 2003) cancer has demonstrated the exis-
NOD-SCID mouse model (the SCID leukemia initiating cell, SL-tence of subpopulations of cells, delineated by differential ex-
IC) has a similar phenotype (CD 34/CD 38) to that of normalpression of surface markers, that exclusively contain the ability
SCID-repopulating cells (Lapidot et al., 1994) and to the cellto recapitulate the human disease upon transplantation into
compartment enriched for true human hematopoietic stem cellsrecipient NOD-SCID (non-obese diabetic/severe combined im-
(HSC) (Manz et al., 2002). Furthermore, recurrent cytogeneticmunodeficient) mice. The tumors that develop are phenotypi-
abnormalities associated with leukemia have also been detectedcally very similar to the original human tumor, and serial trans-
in this cell compartment in patients with AML, chronic myeloidplantation of the tumor to secondary recipients confirms the
leukemia (CML), and ALL (Deininger et al., 2000; Haase et al.,true stem cell nature of these subpopulations of malignant cells.
1995; Mehrotra et al., 1995; Quijano et al., 1997). Indeed, theIt has been suggested that the target cells for malignant
Philadelphia chromosome, the cytogenetic hallmark of CML,transformation are adult somatic stem cells (Reya et al., 2001),
can be detected in cells of the myeloid, erythroid, megakaryo-and that oncogenic mutations appropriate the capacity for self-
renewal inherent in these cells. Stem cells persist throughout cytic, and B-lymphoid lineages, suggesting transformation of a
S I G N I F I C A N C E
The existence of cancer stem cells has been demonstrated in leukemias and solid-organ cancers. It has been suggested that they
result from transformation of adult somatic stem cells with inherent self-renewal capacity. We report that some leukemia-associated
oncogenes, but not others, can confer properties of leukemic stem cells to committed murine myeloid progenitors, and exclude
retroviral insertional events as the sole explanation for these findings. These data provide tools for the identification of cellular
programs that confer self-renewal properties to somatic cells previously destined to undergo terminal differentiation and apoptotic
cell death. Characterization of these programs may identify new targets for therapeutic intervention in leukemia, and genes that
confer properties of self-renewal to adult somatic cells for regenerative therapeutic purposes.
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cell with multilineage differentiation potential such as an HSC
(Deininger et al., 2000; Martin et al., 1980).
Alternatively, it has been suggested that committed hemato-
poietic progenitors without self-renewal capacity may also be
potential targets for transformation, and that this could explain
phenotypic differences between leukemias associated with the
same characteristic molecular abnormality (Fialkow et al., 1981;
Griffin and Lowenberg, 1986). However, committed progenitors
have engaged programs for terminal differentiation and apo-
ptotic cell death, and do not have the properties of leukemic
stem cells. It has been recently reported that retroviral transduc-
tion withMLL-ENL confers properties of self-renewal to commit-
ted myeloid progenitors and demonstrates induction of AML
following their transplantation into irradiated mice (Cozzio et al.,
2003). However, although progenitors transduced with transfor-
mation-disabled mutants of MLL-ENL did not engender this
phenotype, these findings did not address whether this is a
capability conferred by all leukemia-associated oncogenes, ei-
ther alone or in concert with possible retroviral integration ef-
fects.
In this study, we tested the hypothesis that all leukemia-
associated oncogenes have the capacity to confer self-renewal
properties of leukemic stem cells to hematopoietic progenitors
that inherently lack the ability to self-renew. We used multipa-
rameter flow cytometry to isolate purified populations of com-
mitted myeloid progenitors that lack self-renewal capacity
(Akashi et al., 1999; Na Nakorn et al., 2002). These populations
were then transduced with either the MOZ-TIF2 (Carapeti et al.,
1988; Deguchi et al., 2003) or BCR-ABL oncogenes (Deininger Figure 1. Schema of in vitro and in vivo experiments used to test the ability
et al., 2000; Sattler and Griffin, 2003; Wong and Witte, 2001), of MOZ-TIF2 and BCR-ABL to confer properties of self-renewal to committed
as representative members of the transcription factor/cofactor myeloid progenitors
or tyrosine kinase fusion oncogene families, respectively, and In brief, flow-sorted CMP and GMP from Ly5.2 mice were transduced with
retroviral vectors expressing the MOZ-TIF2 or BCR-ABL oncogenes along withtheir self-renewal and transformation properties were analyzed
either the neomycin resistance gene or GFP. For the in vitro studies, serialwith in vitro and in vivo systems and compared with similarly
replating assays were performed following the initial selection of neomycin-transduced HSC and whole bone marrow. The contributions of
resistant transduced cells in the first methylcellulose plate. Colonies which
the initial cell of transduction to the eventual phenotype of the formed in the 3rd or 4th plates were subsequently tested for the ability to grow
disease were also assessed utilizing the same experimental in IL-3-supplemented liquid culture, and these cell lines were subsequently
design. transplanted into irradiated mice. In the in vivo studies, CMP and GMP
transduced with vectors expressing MOZ-TIF2 or BCR-ABL and GFP were
directly injected into lethally irradiated congenic Ly5.1 mice and assessedResults
for the development of leukemia. Where leukemia developed in primary
recipients, the long-term self-renewal of the initially transduced progenitors
MOZ-TIF2, but not BCR-ABL, confers properties was further tested in serial transplant of leukemic cells to sublethally irradi-
ated secondary recipients.of self-renewal to committed myeloid
progenitors in vitro
Unmanipulated murine bone marrow has a finite ability to serially
replate in methylcellulose cultures supplemented with cytokines
with small CFU-blast (Figure 2C). Cytospins of single colonies(Lavau et al., 1997). Transduction of whole bone marrow with
derived from either CMP or GMP demonstrated primitive myelo-certain leukemia oncogenes confers the ability to serially replate
monocytic morphology and hemophagocytosis, features evi-in vitro, although the target population(s) of cells that acquire
dent in the human disease associated withMOZ rearrangementsthe ability to serially replate is unknown (Lavau et al., 1997).
(Borrow et al., 1996; Carapeti et al., 1988) (Figure 2D), as wellThe ability of CMP and GMP transduced with MOZ-TIF2 or
as in murine models of leukemia induced byMOZ-TIF2 (DeguchiBCR-ABL to serially replate was tested as shown in the schema
et al., 2003).in Figure 1. CMP or GMP were transduced with MSCV-pgk-Neo
retroviral constructs and selected for G418-resistant transduced
cells in the first plating. In control experiments, untransduced Mutational analysis of MOZ-TIF2 demonstrates
the same domain requirement for self-renewalCMP and GMP did not serially replate (Figure 2A). We also
observed that CMP or GMP transduced with BCR-ABL did not as for leukemic transformation
Leukemia induction by MOZ-TIF2 has been shown to minimallyserially replate, indicating that BCR-ABL lacks the ability to
alter the programs for terminal differentiation and apoptosis in require the nucleosome binding motif of MOZ (abrogated in
the C543G mutant) and the CBP interaction domain of TIF2committed myeloid progenitors. However, in striking contrast,
CMP or GMP transduced with MOZ-TIF2 did serially replate (abrogated by the LXXLL mutant), but histone acetyltransferase
activity ofMOZ is not required (Deguchi et al., 2003). A proposed(Figure 2A). After 4 replatings, the MOZ-TIF2-transduced colo-
nies were small and tightly packed, with morphology consistent mechanism of transformation by MOZ-TIF2, therefore, involves
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Figure 2. In vitro analysis demonstrates thatMOZ-
TIF2, but not BCR-ABL, can confer properties of
self-renewal to committed myeloid progenitors
A: Bar chart of serial replating experiments. In
contrast to untransduced progenitors (normal
HSC, NHSC, NCMP, and NGMP) and progenitors
transduced with BCR-ABL, CMP and GMP trans-
duced with MOZ-TIF2 demonstrated replating
potential to the 4th plating.
B: Serial replating experiments with MOZ-TIF2 mu-
tants, demonstrating that the nucleosomal bind-
ing site (mutated in C543G mutant) and CBP
interaction domain (mutated in LXXLL mutant)
necessary for transformation are also required to
confer serial replating ability. Results presented
are the mean ( SD) of 2 (untransduced HSC,
CMP, GMP, and MOZ-TIF2 mutants) or 3 experi-
ments (BCR-ABL- and MOZ-TIF2-transduced CMP
and GMP) performed in duplicate. The MCID
mutant contains both the nucleosomal binding
site and CBP interaction domain.
C: Representative photomicrographs of 4th
round platings for BCR-ABL- and MOZ-TIF-trans-
duced GMP. While no colonies were seen on the
BCR-ABL plate, numerous small tightly clustered
CFU-blast could be seen in the MOZ-TIF2 plate.
D: Morphology of cells derived from colonies of
the 4th round of plating for MOZ-TIF2-transduced
CMP and GMP. Primitive myelomonocytic cells
were demonstrated with prominent hemopha-
gocytosis (right panels), features of human MOZ-
TIF2-associated AML.
E: Line graph demonstrating the sustained
growth, over 8 weeks, of MOZ-TIF2-trans-
duced CMP and GMP in IL-3-supplemented liq-
uid culture.
aberrant recruitment of CBP to MOZ nucleosome binding sites transduction of whole bone marrow (Figure 5A, and data not
shown). Cell lines derived from MOZ-TIF2-transduced progeni-(Deguchi et al., 2003). To test the requirements for self-renewal
in committed progenitors, CMP and GMP were transduced with tors were also capable of generating AML, with 1 out of 2 GMP
cell lines and 2 of 3 CMP cell lines resulting in AML wheneither the C543G and LXXLL mutants, or the MOZ-CID (MOZ-
CBP interacting domain) mutant containing the minimal domain transplanted into lethally irradiated recipient mice (latency 103–
162 days) (data not shown).requirement for transformation, and were serially replated in
methylcellulose as above. The results (Figure 2B) show serial Taken together, these data indicate that MOZ-TIF2, but not
BCR-ABL, confers the ability to serially replate in vitro, onereplating only for the MOZ-CID, demonstrating that the domain
requirements for self-renewal are the same as for leukemic surrogate for self-renewal that is not present in normal commit-
ted hematopoietic progenitors, nor indeed in normal HSC (Fig-transformation, and link self-renewal to the aberrant transcrip-
tional program initiated by MOZ-TIF2 that contributes to leuke- ure 2A). Importantly, the capacity of MOZ-TIF2 to confer the
ability to serially replate cannot be attributed to retroviral inser-mogenesis.
tional mutagenesis. Retroviral transduction with point mutants
of MOZ-TIF2 that are not leukemogenic, or with an unrelatedMOZ-TIF2-transduced committed progenitors
but fully active leukemia oncogene, BCR-ABL, does not confercan be propagated in liquid culture,
this ability.and these cell lines can induce AML in mice
MOZ-TIF2-transduced CMP and GMP derived from the third
and fourth rounds of replating were amalgamated and could be MOZ-TIF2-, but not BCR-ABL-, transduced committed
myeloid progenitors can generate AML in micesubsequently propagated in liquid culture containing IL-3 (Fig-
ure 2E), demonstrating sustained growth for at least 8 weeks. We next tested the properties of transduced committed progeni-
tors in vivo. CMP, GMP, or whole bone marrow mononuclearMorphological analysis of these cells at subsequent time points
demonstrated a similar phenotype to the initiating colonies (data cells (BM MNC) derived from Ly5.2 mice were transduced with
MOZ-TIF2 or BCR-ABL and directly injected into lethally irradi-not shown). Flow cytometric analysis of the cell lines demon-
strated a similar surface immunophenotype whether they were ated Ly5.1 congenic recipients according to the schema in Fig-
ure 1. The control experiments with unfractionated BM MNCderived from either CMP or GMP, which was similar to the
phenotype observed in MOZ-TIF2 leukemic cells derived from showed that mice transplanted with BM MNC transduced with
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Figure 3. MOZ-TIF2, but not BCR-ABL, generates
leukemia in transduced committed myeloid pro-
genitors
A: Mice transplanted with BCR-ABL-transduced
BM MNC succumb to a fatal myeloproliferative
disease (MPD) within 30 days of transplantation,
while mice transplanted with BCR-ABL-trans-
duced CMP and GMP do not develop an MPD
over a prolonged time period (p  0.0001). In
contrast, mice transplanted with MOZ-TIF2-trans-
duced BM MNC, CMP, and GMP develop AML,
with no significant difference in latency or pene-
trance (p  0.75)
B: Histology of representative mice transplanted
with BCR-ABL- (left panel) and MOZ-TIF2- (right
panel) transduced GMP. No histological abnor-
mality was detected in theBCR-ABL transplanted
mice. In contrast, MOZ-TIF2 transplanted mice
demonstrated the presence of peripheral blood
(PB) and bone marrow (BM) blasts and extensive
tissue infiltration of organs including the liver,
spleen, and lungs by leukemic blasts. Similar con-
trasting histology was demonstrated in mice
transplanted with transduced CMP.
C: Flow cytometric analysis of spleen and bone
marrow single cell suspensions from mice trans-
planted with BCR-ABL and MOZ-TIF2-transduced
GMP. Relative fluorescence for the myeloid
marker Mac-1 and the congenic marker Ly 5.2
are shown on a logarithmic scale. Quadrant
markers segregate positive and negative cells
and quadrant percentages are given. Abnormal
Mac-1-positive Ly5.2 (CD 45.2) leukemic cells
(upper right quadrant) are present in the bone
marrow and spleen of mice transplanted with
MOZ-TIF2- but not BCR-ABL-transduced cells.
D: Southern analysis of proviral integration in
mice transplanted with BCR-ABL- and MOZ-TIF2-
transduced progenitors. Oligoclonal integration
is demonstrated for MOZ-TIF2-transplanted mice,
but no integration is seen with BCR-ABL mice.
either MOZ-TIF2 or BCR-ABL developed AML or a myeloprolif- AML (Figures 3B [right panel], 4A, 4B, and 5A). These features
included leukemic infiltration of the spleen, submandibularerative disease, respectively, with latencies comparable to those
gland, and submental lymph nodes, liver, lung, and bone mar-previously described (Deguchi et al., 2003; Wong and Witte,
row. The presence of leukemic blasts was seen in the peripheral2001) (Figure 3A). In consonance with observations in the serial
blood, and occasional mice demonstrated granulocytic sarco-replating assays, mice transplanted with MOZ-TIF2-transduced
mata. Analysis of the leukemic cells from these mice showedCMP and GMP developed AML, with a similar long latency to
expression of GFP and Ly 5.2 by FACS analysis and oligoclonalmice transplanted with BM MNC (Figure 3A). In contrast, none
retroviral integration by Southern blotting (Figures 3C and 3D).of the mice transplanted with BCR-ABL-transduced CMP or
GMP showed evidence of disease upon sacrifice at between
FACS analysis indicates that the hematopoietic113 and 240 days, a time point at which all mice transplanted
compartment with properties of leukemic stemwith BCR-ABL-transduced BM MNC had been sacrificed for
cells in MOZ-TIF2-associated leukemiasdevelopment of myeloproliferative disease (Figure 3A).
lies downstream of GMP
FACS analysis, gated on the leukemic cell populations by GFP
MOZ-TIF2-associated leukemias are virtually or Ly 5.2 expression, showed that cells derived from CMP, GMP,
indistinguishable regardless of the initial or whole bone marrow had very similar patterns of expression of
cell population transduced surface markers, although the proportion of cells expressing
MOZ-TIF2-associated leukemias arising from transduced com- some markers varied. The surface phenotype of the leukemic
mitted progenitors populations (CMP and GMP) had a similar population was Sca-1-, CD-34-, CD 4-, CD8-, B220-, and CD19-
tissue distribution, histology, and immunophenotype to those negative, and expressed Mac-1 with varying degrees of Gr-1
arising from unfractionated bone marrow, and recapitulated and c-kit positivity (Figure 5A). There was uniform reduction of
myeloid progenitor groups within this leukemia population, withmany of the phenotypic characteristics of human MOZ-TIF2
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Figure 4. MOZ-TIF2 leukemias are almost identical regardless of the initial cell population transduced
A: Tissue distribution of disease is similar for mice transplanted with MOZ-TIF2-transduced BM MNC, CMP, and GMP. Leukemic mice invariably demonstrated
splenomegaly and neck masses resulting from infiltration of the submandibular glands and submental lymph nodes.
B: Representative morphology of peripheral blood (PB) and histology of the submandibular masses (SM mass), spleen, and lung are shown for leukemic
mice transplanted with transduced BM MNC, CMP, and GMP. Primitive myelomonocytic cells were demonstrated in the peripheral blood, infiltrating the
lung parenchyma and effacing the normal splenic and submental lymph node architecture.
undetectable HSC, CMP, or MEP (megakaryocyte erythroid pre- Purified HSC were transduced with MOZ-TIF2 using the same
protocol, and serial replating and direct transplantation assayscursors) and only residual numbers of GMP. However, there
was a population of c-kit/FcRII/CD34 cells that were not were performed as described above for MOZ-TIF2-transduced
CMP or GMP. In consonance with results in CMP and GMP,present in wild-type mice (Figure 5B). Taken together, these
data indicate that there is impaired differentiation associated HSC transduced with MOZ-TIF2 demonstrated serial replating
ability and were able to grow in liquid culture in an IL-3-depen-with the development of leukemia, and that the population of
cells with properties of leukemic stem cells is downstream of dent manner (data not shown). Direct transplantation of MOZ-
TIF2-transduced HSC also led to the development of AML inthe transduced CMP and GMP.
mice with a similar penetrance but a slightly longer latency than
in transduced CMP, GMP, or whole BM MNC, perhaps relatingMOZ-TIF2 transduction of HSC also results in AML
to their lower cell dose and transduction efficiency at trans-that is indistinguishable from other MOZ-TIF2-
plantation (Figure 6A).associated leukemias
The leukemias that developed were indistinguishable mac-We next tested whether MOZ-TIF2 could also engender acute
myeloid leukemia when transduced into the HSC compartment. roscopically from other MOZ-TIF2 associated leukemias, again
CANCER CELL : DECEMBER 2004 591
A R T I C L E
Figure 5. FACS analysis of MOZ-TIF2-associated
leukemias demonstrates that the compartment
with leukemia stem cell properties lies down-
stream of GMP
A: Similar expression patterns of Gr-1, Mac-1,
c-kit, CD45.2, CD19, and B220 are shown for un-
gated leukemic bone marrow cells from mice
transplanted with transduced BM MNC, CMP,
and GMP. Relative fluorescence for the markers
indicated on the x and y axes are shown on a
logarithmic scale. Quadrant markers segregate
positive and negative cells, and quadrant per-
centages are given.
B: Myeloid progenitor analysis of bone marrow
from representative animals transplanted with
MOZ-TIF2-transduced BM MNC, CMP, and GMP.
A wild-type animal (WT) is shown for comparison.
Relative fluorescence for the markers indicated
on the x and y axes are shown on a logarithmic
scale. The values shown represent the percent-
age proportion of total bone marrow cells ana-
lyzed. Stem cell and progenitor populations are
reduced in leukemic bone marrow of all animals.
demonstrating mild splenomegaly and characteristic submental Discussion
masses. Microscopically, the pattern of organ infiltration and
CMP and GMP are populations of cells that are irrevocablythe histological appearance of the leukemic cells were charac-
committed to terminal differentiation and apoptotic cell death.teristic of other MOZ-TIF2-associated leukemias, as was ex-
Remarkably, transduction of these committed progenitors withpression of immunophenotypic markers (Figures 6B and 6C).
MOZ-TIF2 confers properties of self-renewal in serial replatingAnalysis of myeloid progenitor populations also showed these
assays, and induces acute monocytic leukemia that can bepopulations to be reduced (Figure 6D), again suggesting that
serially transferred into secondary recipients.the compartment with self-renewal capacity lies downstream
The histological and immunological phenotypes of theof GMP.
monocytic MOZ-TIF2-associated leukemias are virtually indis-
tinguishable regardless of whether the initially transduced cell
AML induced by transduction of myeloid progenitors population was whole bone marrow mononuclear cells, CMP,
produces leukemia in secondary recipient mice GMP, or HSC. The explanation that we favor for this observation
The long-term self-renewal properties of leukemic cells derived is that MOZ-TIF2 confers a specified phenotype regardless of
from MOZ-TIF2-transduced CMP or GMP were further tested the transduced cell type among whole bone marrow, CMP,
by transplantation into sublethally irradiated secondary recipi- GMP, or HSC populations. The phenotype includes conferring
ents at a range of cell doses from 1  106 bone marrow cells properties of leukemic stem cells, as assessed by serially replat-
down to 1 102 cells (Figure 7A). All recipient mice transplanted ing assays and development of leukemia in vivo that can be
with  1  105 cells developed leukemia with latencies of be- serially transplanted, and impaired differentiation downstream
tween 32 and 53 days, with an occasional mouse transplanted of GMP in the monocytic lineage. A similar pattern of differentia-
with 1  104 cells also developing disease. Mice below the tion has also recently been described for transduction of hema-
threshold dosage of 1  104 did not develop leukemia with a topoietic progenitors with the oncogene MLL-ENL (Cozzio et
follow up of 84 days. The leukemias were histologically and al., 2003).
immunophenotypically indistinguishable from the primary dis- An important question is whether these results can be ex-
ease (Figure 7B and data not shown), and Southern blot analysis plained as a consequence of retroviral insertional mutagenesis.
demonstrated oligoclonal retroviral integration, as did the pri- To address this question, we have undertaken two types of
control experiments. First, we have retrovirally transduced CMPmary disease (data not shown).
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Figure 6. Transduction of HSC with MOZ-TIF2 also
engenders AML in recipient mice
A: Kaplan-Meier graph comparing the latency
and incidence of AML in recipients of MOZ-TIF2-
transduced HSC with transduced CMP, GMP,
and BM MNC.
B and C: Representative histology and immu-
nophenotype from a MOZ-TIF2-transduced HSC-
associated AML demonstrating the similarity to
other MOZ-TIF2-associated leukemias. Relative
fluorescence for the markers indicated on the x
and y axes are shown on a logarithmic scale.
Quadrant markers segregate positive and nega-
tive cells and quadrant percentages are given.
D: Myeloid progenitor analysis, again demon-
strating a decrease in myeloid progenitor sub-
sets, suggesting that the compartment with
self-renewal potential lies downstream of GMP.
Relative fluorescence for the markers indicated
on the x and y axes are shown on a logarithmic
scale.
and GMP withMOZ-TIF2 point mutants that do not cause leuke- affecting differentiation, and is associated with a chronic myelo-
proliferative phenotype characterized by leukocytosis and nor-mia in the murine BMT system using whole bone marrow. These
lack the ability to confer properties of leukemic stem cells to mal differentiation. In contrast, MOZ-TIF2 is associated with
acute monocytic leukemia in humans and in murine models ofCMP or GMP, indicating that retroviral insertional mutagenesis
with nonleukemogenic mutants of MOZ-TIF2 alone is not suffi- disease characterized by impaired hematopoietic differentiation
and properties of self-renewal. This is illustrated in the proposedcient to confer such properties. Second, retroviral transduction
of BCR-ABL did not confer properties of leukemic stem cells to model in Figure 8, where BCR-ABL confers proliferative and
survival signals to the committed myeloid progenitors, whichCMP or GMP. These data demonstrate that retroviral insertional
mutagenesis, even in collaboration with a fully active leukemo- may allow transient expansion of downstream progeny, but
does not confer properties of self-renewal. In contrast, MOZ-genic tyrosine kinase, is not sufficient to cause leukemia. To-
gether, these data argue strongly that retroviral insertional muta- TIF2 confers properties of self-renewal while also impairing my-
eloid differentiation. This allows preleukemic expansion of thisgenesis alone cannot explain these results. However, we cannot
exclude the possibility that an active MOZ-TIF2, but not BCR- compartment and may facilitate the subsequent development
of AML. The basis for the difference between BCR-ABL andABL, can collaborate with mutations induced by retroviral muta-
genesis to confer properties of leukemic stem cells to committed MOZ-TIF2 in conferring properties of leukemic stem cells to
CMP and GMP remains to be discerned, but it is clear thatprogenitors. Limiting dilution analysis indicated that the fre-
quency of the leukemia repopulating cell was low in this assay leukemia-associated oncogenes vary in their ability to do so.
In addition, these data may have important clinical implica-system, similar to data reported in other murine models of leuke-
mia (Lessard and Sauvageau, 2003) and in human leukemic tions for treatment of leukemias associated with the BCR-ABL
oncogene. If, as our data suggests, BCR-ABL signals are dis-cells transplanted into NOC-SCID recipient mice (Bonnet and
Dick, 1997; Hope et al., 2004). Taken together, these data sup- pensable for maintenance of self-renewal, then small molecule
inhibitors of BCR-ABL may not target the relevant “leukemiaport the existence of a subset of leukemic cells that retain long
term self-renewal potential. stem cell” in this disorder (Graham et al., 2002)—indeed, it
appears that imatinib therapy as a single agent, though quiteWhat is the nature of the qualitative difference between
BCR-ABL and MOZ-TIF2 in conferring properties of self-renewal? effective in remission induction, is rarely if ever curative in BCR-
ABL-positive CML (Melo et al., 2003).This remains an important question. There are various qualitative
differences between these two oncogenes. BCR-ABL expres- It is not certain how many, or what type of, leukemia onco-
genes will confer properties of leukemic stem cells to committedsion in humans, and in mouse models, confers proliferative
and/or survival advantage to hematopoietic progenitors without progenitors. However, MLL-ENL has recently been shown to
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Figure 7. Transplantation of leukemic cells from
animals transplanted with MOZ-TIF2-transduced
CMP and GMP causes identical leukemia in sec-
ondary recipients in a cell dose-dependent
manner
A: Kaplan-Meier graph of survival for secondary
recipients transplanted with leukemic cells from
primary mice transplanted with either MOZ-TIF2-
transduced CMP or GMP. All animals trans-
planted with greater than 1  104 cells devel-
oped leukemia, while no animals transplanted
with less than 1  104 developed disease.
B: Representative histology demonstrating the
same morphological appearance and tissue dis-
tribution of MOZ-TIF2 disease in secondary recipi-
ents.
confer similar properties of self-renewal and to generate AML scription factors. For example, there is evidence for increased
in committed myeloid progenitors (Cozzio et al., 2003). We self-renewal of AML1-ETO-expressing progenitors and HSC,
speculate that this ability may be a generic property of certain both in murine models and transduced human CD34 cells (de
leukemia-associated fusion genes involving hematopoietic tran- Guzman et al., 2002; Mulloy et al., 2002, 2003; Higuchi et al.,
2002; Rhoades et al., 2000; Tonks et al., 2003), although as yet,
no evidence exists for the reestablishment of such properties
in progenitors which inherently lacked self-renewal potential.
In addition, analysis of gene expression profiles in the U937
hematopoietic precursor cell line stably expressing AML1-ETO,
PML-RAR	, or PLZF-RAR	 demonstrated the induction of
genes involved in the maintenance of the stem cell phenotype
(Alcalay et al., 2003; Muller-Tidow et al., 2004). This suggests
that induction of self-renewal by a number of transcription factor
fusions may have a wider relevance in the pathogenesis of AML.
It should be noted that our data do not exclude the possibility
that leukemogenic mutations often occur in HSC, as expression
of MOZ-TIF2 in this population also resulted in leukemia. The
data only indicate that if such mutations arise in committed
progenitors, they are capable of transforming committed pro-
genitors to cells with the properties of leukemia stem cells.
However, use of this assay in committed progenitors to compare
BCR-ABL or inactive MOZ-TIF2 mutants with MOZ-TIF2 itself
should allow for definition of the transcriptional programs that
confer properties of self-renewal to hematopoietic stem cells.
These programs may be targets for therapeutic intervention in
leukemia, and may also provide strategies for conferring proper-Figure 8. Development of AML is facilitated by the properties of self-renewal
conferred to myeloid progenitors by MOZ-TIF2 ties of self-renewal to adult somatic cells in other therapeutic
The normal differentiation of an HSC to a granulocyte through specific contexts, such as tissue regeneration.
myeloid progenitor intermediates is shown in the left column. In the center
column, transduction of myeloid progenitors with BCR-ABL may provide Experimental procedures
a proliferation and survival signal to these progenitors without impairing
differentiation. This in turn may lead to an expansion of the granulocyte
Cell staining and sorting
compartment, but without self-renewal is insufficient to generate leukemia
Bone marrow mononuclear cells were flushed from the leg bones of C57B6in the recipient mice. In contrast, transduction of myeloid progenitors with
mice (Taconic, Germantown, NY). For transplants using transduced boneMOZ-TIF2 (right column) both restores self-renewal to this compartment and
marrow mononuclear cells, the mice were treated with 5FU 150 mg/kgimpairs its further differentiation. In combination, these properties allow pre-
(Sigma, St. Louis, MO) intraperitoneally 6 days prior to sacrifice. The cellsleukemic expansion of the compartment and may facilitate the develop-
ment of AML upon the acquisition of further cooperating mutations. were then washed and the red cells lysed on ice with RBC lysis buffer
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(Gentra, Minneapolis, MN). HSC, CMP, and GMP populations were sorted conjugated with fluorescein isothiocyanate (FITC), phycoerthyrin (PE), or
biotin. Binding of biotinylated primary antibodies was detected using PE-and analyzed as previously reported (Na Nakorn et al., 2002).
conjugated streptavidin (Immunotech, Westbrook, ME) or FITC-conjugated
avidin (Southern Biotechnology, Birmingham, AL). Cells were washed onceRetroviral constructs, retroviral transduction,
in staining buffer followed by two-colored flow cytometric analysis with aand bone marrow transplant assay
FACScan (Becton Dickinson, San Jose, CA). A minimum of 10,000 eventsThe MOZ-TIF2, MOZ-TIF2 mutants, and BCR-ABL MSCV-pgk-Neo and
was acquired showing FITC and PE fluorescence signals of viable cellsMSCV-IRES-GFP vectors and the production of retroviral supernatants are
gated on the basis of forward and side scatter signals.as previously described (Dash et al., 2002; Deguchi et al., 2003). Bone
marrow MNC, HSC, and CMP were all incubated overnight in IMDM (Life
Technologies, Rockville, MD) supplemented with murine IL-11 10 
g/ml and Southern blotting for proviral insertion and clonality
Genomic DNA was prepared from single-cell suspensions of tumor cellsSCF 10 
g/ml (both R&D Systems, Minneapolis, MN), and transduced the
next day. GMP cells were transduced immediately following sorting. For using a PUREGENE DNA isolation kit according to the manufacturer’s proto-
col (Gentra Systems, Minneapolis, MN). Twenty micrograms of genomictransduction, cells were plated in IMDM supplemented with IL-11 and SCF
in 6-well plates (Becton Dickinson, Franklin Lakes, NJ) coated with 40 
g/ml DNA was digested with EcoRI, which cuts once within the proviral sequence
and once within the integrated locus, and was subjected to electrophoresisFibronectin (Takara, Japan). Retroviral supernatant was added along with
Polybrene 4 
g/ml and the cells were incubated overnight at 37C in 5% and hybridization according to standard protocols.
CO2. The cells were then harvested, counted, and resuspended in 0.5 ml
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